Burden of Adults Hospitalized With Group B Streptococcal Infection.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
13 10 2021
Historique:
received: 05 12 2019
accepted: 17 03 2020
pubmed: 20 3 2020
medline: 25 2 2022
entrez: 20 3 2020
Statut: ppublish

Résumé

The burden of noninvasive group B Streptococcus (GBS) infections in adults is unknown. We determined population-based rates of hospitalization where invasive or noninvasive GBS infections were identified among US adults in a defined catchment area. We identified adults with clinical and laboratory-confirmed evidence of GBS infection from January 2014 through December 2016 from 6 hospitals in Louisville, Kentucky. Invasive disease was defined as GBS isolated from a normally sterile site. Among 1076 adults with GBS infection, the median age was 52 years, 51% were male, and 89% had ≥1 chronic medical condition. The most prevalent infection sites were skin and soft tissue (39%), urinary tract (23%), bone and joint (16%), and bloodstream (11%). Forty percent of infections were polymicrobial. The annual incidence of GBS-associated hospitalization was 73 per 100 000 adults and 68 and 100 per 100 000 for patients aged 18-64 and ≥ 65 years, respectively. For every invasive GBS infection, 3.7 noninvasive infections occurred. Our population-based study outlines the full burden of GBS-associated hospitalization in adults and found incidence rates comparable to those of pneumococcal disease, where vaccines are recommended. Noninvasive disease was 3-4 times more common than invasive disease, suggesting that the GBS burden among adults is considerably greater than previously recognized.

Sections du résumé

BACKGROUND
The burden of noninvasive group B Streptococcus (GBS) infections in adults is unknown. We determined population-based rates of hospitalization where invasive or noninvasive GBS infections were identified among US adults in a defined catchment area.
METHODS
We identified adults with clinical and laboratory-confirmed evidence of GBS infection from January 2014 through December 2016 from 6 hospitals in Louisville, Kentucky. Invasive disease was defined as GBS isolated from a normally sterile site.
RESULTS
Among 1076 adults with GBS infection, the median age was 52 years, 51% were male, and 89% had ≥1 chronic medical condition. The most prevalent infection sites were skin and soft tissue (39%), urinary tract (23%), bone and joint (16%), and bloodstream (11%). Forty percent of infections were polymicrobial. The annual incidence of GBS-associated hospitalization was 73 per 100 000 adults and 68 and 100 per 100 000 for patients aged 18-64 and ≥ 65 years, respectively. For every invasive GBS infection, 3.7 noninvasive infections occurred.
CONCLUSIONS
Our population-based study outlines the full burden of GBS-associated hospitalization in adults and found incidence rates comparable to those of pneumococcal disease, where vaccines are recommended. Noninvasive disease was 3-4 times more common than invasive disease, suggesting that the GBS burden among adults is considerably greater than previously recognized.

Identifiants

pubmed: 32188975
pii: 5809927
doi: 10.1093/infdis/jiaa110
pmc: PMC8561246
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1170-1178

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Expert Rev Anti Infect Ther. 2019 Jan;17(1):17-25
pubmed: 30518267
Open Forum Infect Dis. 2018 Jun 08;5(6):ofy030
pubmed: 29977953
N Engl J Med. 1993 Jun 24;328(25):1807-11
pubmed: 8502269
Curr Opin Infect Dis. 2018 Apr;31(2):104-112
pubmed: 29337704
Int J Infect Dis. 2019 Jun;83:116-129
pubmed: 31028879
Clin Infect Dis. 2017 Nov 13;65(11):1806-1812
pubmed: 29020164
JAMA Intern Med. 2019 Apr 1;179(4):479-488
pubmed: 30776079
Clin Infect Dis. 2001 Aug 15;33(4):556-61
pubmed: 11462195
JAMA. 1991 Aug 28;266(8):1112-4
pubmed: 1865545
J Pediatr. 1973 Dec;83(6):919-25
pubmed: 4585831
Epidemiol Infect. 2015 Nov;143(15):3343-50
pubmed: 26418351
MMWR Recomm Rep. 2010 Nov 19;59(RR-10):1-36
pubmed: 21088663
J Infect Dis. 2019 Jun 5;220(1):105-115
pubmed: 30778554
N Engl J Med. 2015 Feb 26;372(9):835-45
pubmed: 25714161
MMWR Recomm Rep. 2002 Aug 16;51(RR-11):1-22
pubmed: 12211284
Infection. 2008 Mar;36(2):100-11
pubmed: 18193384
J Med Microbiol. 1998 Jul;47(7):649-52
pubmed: 9839570
MMWR Morb Mortal Wkly Rep. 2014 Sep 19;63(37):822-5
pubmed: 25233284
Clin Infect Dis. 2013 Sep;57(5):682-8
pubmed: 23845950
Clin Infect Dis. 2009 Jul 1;49(1):85-92
pubmed: 19480572

Auteurs

John M McLaughlin (JM)

Pfizer Vaccines, Collegeville, Pennsylvania, USA.

Paula Peyrani (P)

Pfizer Vaccines, Collegeville, Pennsylvania, USA.

Stephen Furmanek (S)

Division of Infectious Diseases, University of Louisville, Louisville, Kentucky, USA.

Farid L Khan (FL)

Pfizer Vaccines, Collegeville, Pennsylvania, USA.

Angela Quinn (A)

Pfizer Vaccines, Collegeville, Pennsylvania, USA.

Luis Jodar (L)

Pfizer Vaccines, Collegeville, Pennsylvania, USA.

Julio Ramirez (J)

Division of Infectious Diseases, University of Louisville, Louisville, Kentucky, USA.

David L Swerdlow (DL)

Pfizer Vaccines, Collegeville, Pennsylvania, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH